Abstract
Purpose :
Intravitreal dexamethasone implant (Ozurdex®) or combined intravitreal bevacizumab and subtenon triamcinolone injection were used to subside macular edema(ME) in patients with branch retinal vein occlusion(BRVO).
We performed a prospective clinical study that we wanted to know the differences of between Ozurdex® and combined therapy at the efficacy to subside ME and effect to the IOP in patients with recurred BRVO.
Methods :
The 22 participants visited in Kangdong sacred heart hospital, from 2013 to 2015 due to BRVO.
Inclusion criteria were BCVA < 0.4, central macular thickness(CMT) > 300 um in Optical coherence tomography(OCT), previous one time intravitreal Ozurdex® injection history due to BRVO with ME, recurred BRVO with ME. Exclusion criteria were retinal disease except BRVO, steroid responder, IOP > 20mmHg at the baseline. We performed ophthalmic examinations of visual acuity, BCVA, IOP (Goldmann applanation tonometer), fundus photography, autofluorescence photography, OCT (Time domain and spectralis) at the baseline and 1, 2, 3 months after injections. The relationship between initial and follow-up examination was analyzed using Paired t-test SPSS 18.0 (SPSS inc., Chicago, Illinos, USA) and P value of < 0.05.
Results :
Average BCVA was 0.33 at baseline, 0.58 at 3 months after injection (p-value 0.01) in Ozurdex® group, 0.27 at baseline, 0.47 at 3 months (p-value 0.03) in combined therapy group.
Average IOP was 13.55mmHg at baseline,15.09 at 3 months (p-value 0.1) in Ozurdex® group, 13.45 at baseline, 13.18 at 3 months (p-value 0.75) in combined therapy group.
Average CMT was 578.6 um at baseline, 366.9 um at 3 months (p-value 0.002) in Ozurdex® group, 575.6 um at baseline, 397.2 um at 3 months (p-value 0.001) in combined therapy group.
Differences between baseline and 3 months after injection were as followed. (figure)
Conclusions :
The central macular thickness and BCVA in both groups were turned out statistically improved during 3 months after injection. But the differences of BCVA, IOP, CMT between baseline and 3 months after injection in both groups were not statistically significant. Both dexamethasone implant and combined therapy can be effective options to subside macular edema in recurred branch retinal vein occlusion.
This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.